AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Credit card points can unlock a variety of rewards, from travel to cashback. Discover the possibilities and make the most of your points.
28,188 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
As CI&T launches into 2026, investors are scanning for momentum, margin resilience, and strategic bets. This deep div...
Lockup terms can shape the first days of a stock's life after an IPO. This guide explains standard practices, what an...
A potential energy shock could ripple through retail margins and consumer demand this summer. This guide explains wha...
Is Pfizer stock undervalued in the crowded healthcare space? This deep dive weighs cash flow, dividends, pipeline pot...
Dell Technologies grabbed headlines as its AI-focused strategy started to show momentum. This piece breaks down why d...
Investors are eyeing AAR's AIR 2026 earnings call for clues on aftermarket demand, margins, and guidance. This articl...
Berkshire Hathaway kicked off the year with bold portfolio changes. In Q1, the company swapped key holdings and redir...
Investors cheered a decisive move higher as Okta unveiled AI-powered growth opportunities. The stock touched a new 52...
Nvidia sits at the crossroads of AI demand and high-performance computing. This article dives into why prediction: nv...
When A-list stars anchor niche sports stories, it signals a shift in entertainment investing. This article unpacks wh...
Microsoft delivered a powerful May with a 10.4% jump, but June brought a dampening mood. This article breaks down wha...